Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

Learn about the disparities in immunotherapy access for Black patients with triple-negative breast cancer (TNBC) compared to ...

Disease-free survival is significantly longer with adjuvant pembrolizumab than observation among patients with high-risk ...

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic ...

EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers ...

Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared ...

After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...